Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
Summit Announces Closing of Private Placement of $50 Million
Details : Funds to be used for continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole; Preparatory activities to support the commercial launch of ridinilazole; Development of early-stage research projects using Discuva Platfo...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
LOOKING FOR A SUPPLIER?
Reset All
